|
| Status |
Public on May 11, 2021 |
| Title |
Next Generation Sequencing Quantitative Analysis of TEAD Palmitoylation Inhibitor MGH-CP1 in Breast Cancer Cell Line |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Purpose: The goal of this study is to understand the signaling pathway alteration in cancer cell line treated with TEAD palmitoylation inhibitor MGH-CP1, and to further validate TEAD inhibitor for specifity in TEAD-YAP interuption.
Methods:Breast cancer cell line MDA-MB-231 was chosen to be treated with TEAD palmitoylation inhibitor MGH-CP1 at 10μM for 24 hours. Total RNA was isolated for the analysis. RNA samples were sent to Novogen for library construction, RNA sequencing and raw data process.
Results: MGH-CP1 specifically blocks TEAD transcriptional activity compared with YAP/TAZ siRNA in MDA-MB-231 cells.
Conclusions: Our study privides gene expression profiling evidence to validate our TEAD palmitoylation inhibitor MGH-CP1 as specific small molecule to block TEAD transcriptional activity.
We report the application of next generation sequencing technology for high-throughput profiling of TEAD palmitoylation inhibitor MGH-CP1 in breast cancer cells.
|
| |
|
| Overall design |
Examination of vehicle control and MGH-CP1 in one breast cancer cell line.
*** Submitter has indicated raw files are no longer available.
|
| |
|
| Contributor(s) |
Wu X, Sun Y |
| Citation(s) |
32259481 |
| Submission date |
Nov 14, 2019 |
| Last update date |
May 11, 2021 |
| Contact name |
Yang Sun |
| E-mail(s) |
yangsunf@outlook.com
|
| Phone |
6177248603
|
| Organization name |
Massachusetts General Hospital
|
| Department |
CBRC
|
| Street address |
149 13th Street, CBRC 3050E
|
| City |
Charlestown |
| State/province |
MA |
| ZIP/Postal code |
02129 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (4)
|
|
| Relations |
| BioProject |
PRJNA589597 |
Less...
More...